Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study

Documenti analoghi

• Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data
  di: Huijun Chen, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers
  di: Tianxing Liu, et al.
  Pubblicazione: (2024)
• Safety, pharmacokinetics, and pharmacodynamics in healthy Chinese volunteers treated with SC0062, a highly selective endothelin‐A receptor antagonist
  di: Yun Liu, et al.
  Pubblicazione: (2024)
• Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
  di: Byung Hak Jin, et al.
  Pubblicazione: (2024)
• Phase I clinical trial evaluating the safety, tolerance, pharmacokinetics and pharmacodynamics of HSK21542 injection in healthy volunteers
  di: Rong Shao, et al.
  Pubblicazione: (2024)